Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs
Purpose. Topotecan and belotecan are camptothecin derivatives that are used to treat small cell lung cancer (SCLC). This study compared the toxicities and efficacies of belotecan and topotecan monotherapies in patients with SCLC. Methods. We retrospectively reviewed data from 94 patients with SCLC (...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Canadian Respiratory Journal |
| Online Access: | http://dx.doi.org/10.1155/2016/3576201 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832547645820764160 |
|---|---|
| author | Yeon Hee Park Chae Uk Chung Bo Mi Park Myoung Rin Park Dong Il Park Jae Young Moon Hee Sun Park Jin Hwan Kim Sung Soo Jung Ju Ock Kim Sun Young Kim Jeong Eun Lee |
| author_facet | Yeon Hee Park Chae Uk Chung Bo Mi Park Myoung Rin Park Dong Il Park Jae Young Moon Hee Sun Park Jin Hwan Kim Sung Soo Jung Ju Ock Kim Sun Young Kim Jeong Eun Lee |
| author_sort | Yeon Hee Park |
| collection | DOAJ |
| description | Purpose. Topotecan and belotecan are camptothecin derivatives that are used to treat small cell lung cancer (SCLC). This study compared the toxicities and efficacies of belotecan and topotecan monotherapies in patients with SCLC. Methods. We retrospectively reviewed data from 94 patients with SCLC (with or without prior chemotherapy) who were treated using belotecan monotherapy (n=59, 188 cycles) or topotecan monotherapy (n=35, 65 cycles) between September 2003 and December 2011. Results. Thrombocytopenia occurred during 42% and 61.5% of the belotecan and topotecan cycles, respectively (p=0.007). Significant differences between belotecan and topotecan were also observed for grade 4/5 lung infection (3.2% versus 10.8%, resp.; p=0.003), all-grade headache (3.2% versus 10.8%, resp.; p=0.017), and grade 4/5 increased liver enzymes (0.5% versus 4.6%, resp.; p=0.023). The median TTPDs, CSSs, and OSs were 14 months and 11.6 months (p=0.646), 10 months and 7 months (p=0.179), and 34.5 months and 21.4 months (p=0.914) after belotecan and topotecan monotherapy, respectively. Conclusions. Belotecan monotherapy may be safer than topotecan monotherapy in SCLC patients. And in terms of efficacy, belotecan could be comparable to topotecan monotherapy. |
| format | Article |
| id | doaj-art-76f534a8b26a4912a7eb1711660ce77c |
| institution | Kabale University |
| issn | 1198-2241 1916-7245 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Respiratory Journal |
| spelling | doaj-art-76f534a8b26a4912a7eb1711660ce77c2025-02-03T06:43:53ZengWileyCanadian Respiratory Journal1198-22411916-72452016-01-01201610.1155/2016/35762013576201Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin AnalogsYeon Hee Park0Chae Uk Chung1Bo Mi Park2Myoung Rin Park3Dong Il Park4Jae Young Moon5Hee Sun Park6Jin Hwan Kim7Sung Soo Jung8Ju Ock Kim9Sun Young Kim10Jeong Eun Lee11Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Republic of KoreaDepartment of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Republic of KoreaDepartment of Internal Medicine, College of Medicine, Eulji University, Daejeon, Republic of KoreaDepartment of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Republic of KoreaDepartment of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Republic of KoreaDepartment of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Republic of KoreaDepartment of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Republic of KoreaDepartment of Radiology, College of Medicine, Chungnam National University, Daejeon, Republic of KoreaDepartment of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Republic of KoreaDepartment of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Republic of KoreaDepartment of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Republic of KoreaDepartment of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Republic of KoreaPurpose. Topotecan and belotecan are camptothecin derivatives that are used to treat small cell lung cancer (SCLC). This study compared the toxicities and efficacies of belotecan and topotecan monotherapies in patients with SCLC. Methods. We retrospectively reviewed data from 94 patients with SCLC (with or without prior chemotherapy) who were treated using belotecan monotherapy (n=59, 188 cycles) or topotecan monotherapy (n=35, 65 cycles) between September 2003 and December 2011. Results. Thrombocytopenia occurred during 42% and 61.5% of the belotecan and topotecan cycles, respectively (p=0.007). Significant differences between belotecan and topotecan were also observed for grade 4/5 lung infection (3.2% versus 10.8%, resp.; p=0.003), all-grade headache (3.2% versus 10.8%, resp.; p=0.017), and grade 4/5 increased liver enzymes (0.5% versus 4.6%, resp.; p=0.023). The median TTPDs, CSSs, and OSs were 14 months and 11.6 months (p=0.646), 10 months and 7 months (p=0.179), and 34.5 months and 21.4 months (p=0.914) after belotecan and topotecan monotherapy, respectively. Conclusions. Belotecan monotherapy may be safer than topotecan monotherapy in SCLC patients. And in terms of efficacy, belotecan could be comparable to topotecan monotherapy.http://dx.doi.org/10.1155/2016/3576201 |
| spellingShingle | Yeon Hee Park Chae Uk Chung Bo Mi Park Myoung Rin Park Dong Il Park Jae Young Moon Hee Sun Park Jin Hwan Kim Sung Soo Jung Ju Ock Kim Sun Young Kim Jeong Eun Lee Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs Canadian Respiratory Journal |
| title | Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs |
| title_full | Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs |
| title_fullStr | Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs |
| title_full_unstemmed | Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs |
| title_short | Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs |
| title_sort | lesser toxicities of belotecan in patients with small cell lung cancer a retrospective single center study of camptothecin analogs |
| url | http://dx.doi.org/10.1155/2016/3576201 |
| work_keys_str_mv | AT yeonheepark lessertoxicitiesofbelotecaninpatientswithsmallcelllungcanceraretrospectivesinglecenterstudyofcamptothecinanalogs AT chaeukchung lessertoxicitiesofbelotecaninpatientswithsmallcelllungcanceraretrospectivesinglecenterstudyofcamptothecinanalogs AT bomipark lessertoxicitiesofbelotecaninpatientswithsmallcelllungcanceraretrospectivesinglecenterstudyofcamptothecinanalogs AT myoungrinpark lessertoxicitiesofbelotecaninpatientswithsmallcelllungcanceraretrospectivesinglecenterstudyofcamptothecinanalogs AT dongilpark lessertoxicitiesofbelotecaninpatientswithsmallcelllungcanceraretrospectivesinglecenterstudyofcamptothecinanalogs AT jaeyoungmoon lessertoxicitiesofbelotecaninpatientswithsmallcelllungcanceraretrospectivesinglecenterstudyofcamptothecinanalogs AT heesunpark lessertoxicitiesofbelotecaninpatientswithsmallcelllungcanceraretrospectivesinglecenterstudyofcamptothecinanalogs AT jinhwankim lessertoxicitiesofbelotecaninpatientswithsmallcelllungcanceraretrospectivesinglecenterstudyofcamptothecinanalogs AT sungsoojung lessertoxicitiesofbelotecaninpatientswithsmallcelllungcanceraretrospectivesinglecenterstudyofcamptothecinanalogs AT juockkim lessertoxicitiesofbelotecaninpatientswithsmallcelllungcanceraretrospectivesinglecenterstudyofcamptothecinanalogs AT sunyoungkim lessertoxicitiesofbelotecaninpatientswithsmallcelllungcanceraretrospectivesinglecenterstudyofcamptothecinanalogs AT jeongeunlee lessertoxicitiesofbelotecaninpatientswithsmallcelllungcanceraretrospectivesinglecenterstudyofcamptothecinanalogs |